Improving Lives Through
Innovative Diagnostic Solutions
AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests.
Improving Lives Through
Innovative Diagnostic Solutions
AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests.
oncological
solutions
AXIM Biotech is in development of a rapid (10-minute) diagnostic test that detects active biomarkers for early detection of cancer
OPHTHALMOLOGICAL DIAGNOSTICS
AXIM has developed and commercialized two point-of-care ophthalmological diagnostic solutions focused on diagnosis of Dry Eye Disease (DED)
DIAGNOSTIC
TEST DEVELOPMENT
Through AXIM’s vertically integrated research and development platform, AXIM is capable of developing diagnostic solutions for a variety of conditions – based on the needs of the client
oncological
solutions
AXIM Biotech is in development of a rapid (10-minute) diagnostic test that detects active biomarkers for early detection of cancer
OPHTHALMOLOGICAL DIAGNOSTICS
AXIM has developed and commercialized two point-of-care ophthalmological diagnostic solutions focused on diagnosis of Dry Eye Disease (DED)
DIAGNOSTIC
TEST DEVELOPMENT
Through AXIM’s vertically integrated research and development platform, AXIM is capable of developing diagnostic solutions for a variety of conditions – based on the needs of the client
About AXIM
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease.
Axim Biotechnologies Files Pre-Submission with FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic Test
San Diego, CA – June 24, 2025 – Axim Biotechnologies, Inc. (OTCQB: AXIM), a leading developer of rapid diagnostic testing for ocular and systemic conditions, today announced that it has filed a Pre-Submission (Pre-Sub Q) with the U.S. Food and Drug Administration...
AXIM Biotechnologies Receives Medical Device Manufacturing License
State of California Department of Public Heath Food and Drug Branch Issues the Company a License for Manufacturing of its Diagnostic Assays SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the...
VIDEO: AXIM® Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...